Boehringer Ingelheim, OSE Immunotherapeutics expand partnership beyond cancer

Boehringer In­gel­heim is build­ing on its col­lab­o­ra­tion with OSE Im­munother­a­peu­tics by in­ves­ti­gat­ing two clin­i­cal-stage on­col­o­gy pro­grams in car­dio-re­nal-meta­bol­ic dis­ease and adding a third pre­clin­i­cal can­cer project through a sep­a­rate as­set pur­chase.

The Ger­man drug­mak­er is set to spend €25.3 mil­lion ($27.4 mil­lion) on a “par­tial roy­al­ty buy-out” of two an­ti-SIR­Pα as­sets part­nered with OSE. The drugs, dubbed BI 765063 and BI 770371, are in Phase 1 sol­id tu­mor tri­als but will now al­so be in­ves­ti­gat­ed in car­dio-re­nal-meta­bol­ic dis­ease with a Phase 2 study planned for lat­er in the year, Boehringer said in a re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.